Quotes 5-day view Delayed Nse India Stock Exchange
03/01/2021
03/02/2021
03/03/2021
03/04/2021
03/05/2021
Date
395.65(c)
398(c)
402.7(c)
399.75(c)
394.6(c)
Last
2 691 673
2 769 928
2 975 783
1 939 204
1 607 741
Volume
+1.40% +0.59% +1.18% -0.73% -1.29% Change
Sales 2021
73 680 M 1 007 M 1 007 M
Net income 2021
7 298 M 99,8 M 99,8 M
Net Debt 2021
25 716 M 352 M 352 M
P/E ratio 2021
65,3x
Yield 2021
0,28%
Sales 2022
90 511 M 1 237 M 1 237 M
Net income 2022
11 400 M 156 M 156 M
Net Debt 2022
19 576 M 268 M 268 M
P/E ratio 2022
40,7x
Yield 2022
0,36%
Capitalization
468 B 6 383 M 6 394 M
EV / Sales 2021
6,70x
EV / Sales 2022
5,38x
Nbr of Employees
12 609
Free-Float
33,5%
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and...
Notations Surperformance© of Biocon Limited
Trading Rating : Investor Rating :
All news about BIOCON LIMITED
News in other languages on BIOCON LIMITED
Indian pharma firms go local seeking to end reliance on China
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIOCON LIMITED
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
20
Average target price
407,95 INR
Last Close Price
394,60 INR
Spread / Highest target
26,7%
Spread / Average Target
3,38%
Spread / Lowest Target
-39,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
